14 results
S-1
EX-10.18
RVNC
Revance Therapeutics Inc
31 Dec 13
IPO registration
12:00am
of assuring Product quality and compliance with agreed-upon manufacturing procedures. Subject to Section 6.3(b), such general audits shall [***].
(b … occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action.
“Annual Product Quality Review
10-K
ouf8l
28 Mar 14
Annual report
12:00am
DRS
60o1oejbuk6
19 Apr 13
Draft registration statement
12:00am
424B4
og8xc l0x
6 Feb 14
Prospectus supplement with pricing info
12:00am
S-1
1804216yj0xr 2smy
31 Dec 13
IPO registration
12:00am
- Prev
- 1
- Next